Table 2.
Patient characteristics.
| Total |
PKD1 Truncated |
PKD1 Non-Truncated |
PKD2 Truncated |
PKD2 Non-Truncated |
p-Value | |
|---|---|---|---|---|---|---|
| Patients, n (%) | 309 (100) | 139 (45.0) | 86 (27.8) | 68 (22.0) | 16 (5.2) | |
| Age, median (IQR) | 48 (41–55) | 46 (38–50) | 46 (41–54) | 52 (46–62) | 54 (48–59) | <0.001 |
| Sex | 0.78 | |||||
| Female | 176 | 79 | 49 | 37 | 11 | |
| Male | 133 | 60 | 37 | 31 | 5 | |
| Height, m, median (IQR) | 1.65 (1.58–1.72) | 1.66 (1.60–1.73) | 1.65 (1.60–1.72) | 1.64 (1.56–1.70) | 1.62 (1.57–1.66) | 0.021 |
| BMI, kg/m2, median (IQR) | 22.0 (20.2–24.6) | 21.7 (20.0–24.0) | 22.7 (20.7–25.3) | 21.9 (20.6–25.1) | 23.0 (21.3–24.1) | 0.304 |
| TKV, mL, median (IQR) | 1224.0 (808.0–1720.5) | 1277.0 (840.0–1760.8) | 1108.5 (755.2–1566.5) | 1240.5 (809.8–1695.1) | 1344 (900.8–3048.3) | 0.016 |
| HtTKV, mL/m, median (IQR) | 748.0 (483.3–1002.2) | 761.0 (525.5–1016.4) | 694.1 (440.0–929.7) | 753.9 (490.3–1033.6) | 877.4 (575.6–1957.0) | 0.011 |
| ΔeGFR/year, mL/min/1.73 m2, median (IQR) | −3.10 (−5.69 to −1.0) | −3.65 (−6.39 to −1.35) | −3.41 (−5.69 to −1.66) | −2.04 (−5.01 to −0.60) | −2.22 (−5.00 to −0.58) | 0.166 |
| Hypertension before 35 years of age | 0.118 | |||||
| Yes | 41 | 24 | 12 | 4 | 1 | |
| No | 268 | 115 | 74 | 64 | 15 | |
| Urologic event before 35 years of age | 0.201 | |||||
| Yes | 117 | 44 | 37 | 31 | 5 | |
| No | 192 | 95 | 49 | 37 | 11 | |
| Mayo subclass | 0.01 | |||||
| Class 1A | 19 | 4 | 7 | 7 | 1 | |
| Class 1B | 103 | 39 | 29 | 29 | 6 | |
| Class 1C | 121 | 58 | 28 | 30 | 5 | |
| Class 1D | 54 | 29 | 20 | 2 | 3 | |
| Class 1E | 12 | 9 | 2 | 0 | 1 |
Data are presented as either median (IQR) or n (%). IQR: interquartile range, BMI: body mass index, TKV: total kidney volume, HtTKV: height-adjusted total kidney volume, eGFR: estimated glomerular filtration rate, ΔeGFR/year: represents the 1-year change in eGFR calculated using the least-squares method based on the change in eGFR values before tolvaptan treatment.